SIGA Technologies  

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile SIGA Technologies (SIGAQ) is a New York based pharmaceutical company focused on development of therapeutic solutions for some of the most lethal disease causing pathogens including Ebola & other dangerous viruses.

17 SEP 2014: Received Bankruptcy Court approval of "first-day" motions.

16 SEP 2014: Company filed a voluntary petition for relief under Chapter 11 of the US Bankruptcy Code in the US Bankruptcy Court.

Note: Products & Financials modules of EvaluatePharma® to be updated for the MAY 2015 monthly update.
Listed or Private Company Listed
Company Classification Biotechnology
Country USA
Company Website Website
Technology Platform Profile
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
11/08/2014 10 Aug: Company announces that the Delaware Court of Chancery issued a memorandum opinion on 8 Aug ordering SIGA to pay PharmAthene damages for the value of its lost profits from SIGA's smallpox antiviral, tecovirimat. 90 -38.7% -57

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
SIGA Technologies 1 22


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now